161 related articles for article (PubMed ID: 36313707)
1. Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death.
Kuang C; Tong J; Ermine K; Cai M; Dai F; Hao S; Giles F; Huang Y; Yu J; Zhang L
Front Oncol; 2022; 12():1018775. PubMed ID: 36313707
[TBL] [Abstract][Full Text] [Related]
2. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
3. The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells.
van Gils N; Martiañez Canales T; Vermue E; Rutten A; Denkers F; van der Deure T; Ossenkoppele GJ; Giles F; Smit L
Hemasphere; 2021 Aug; 5(8):e610. PubMed ID: 34258514
[TBL] [Abstract][Full Text] [Related]
4. BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade.
Tong J; Tan X; Risnik D; Gao M; Song X; Ermine K; Shen L; Wang S; Yu J; Zhang L
Oncogene; 2021 Dec; 40(48):6566-6578. PubMed ID: 34615996
[TBL] [Abstract][Full Text] [Related]
5. Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma.
Ryan KR; Giles F; Morgan GJ
Eur J Haematol; 2021 Jan; 106(1):90-99. PubMed ID: 32997383
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734.
Spriano F; Gaudio E; Cascione L; Tarantelli C; Melle F; Motta G; Priebe V; Rinaldi A; Golino G; Mensah AA; Aresu L; Zucca E; Pileri S; Witcher M; Brown B; Wahlestedt C; Giles F; Stathis A; Bertoni F
Blood Adv; 2020 Sep; 4(17):4124-4135. PubMed ID: 32882003
[TBL] [Abstract][Full Text] [Related]
7. Encorafenib enhances TRAIL-induced apoptosis of colorectal cancer cells dependent on p53/PUMA signaling.
Sun Z; Qiu Z; Ma B; Wang Z
Cytotechnology; 2021 Feb; 73(1):63-70. PubMed ID: 33505114
[TBL] [Abstract][Full Text] [Related]
8. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer.
Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944
[TBL] [Abstract][Full Text] [Related]
9. Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models.
Liu XM; Xia SY; Long W; Li HJ; Yang GQ; Sun W; Li SY; Du XH
World J Gastrointest Oncol; 2023 Feb; 15(2):332-342. PubMed ID: 36908321
[TBL] [Abstract][Full Text] [Related]
10. BET Inhibitors Potentiate Chemotherapy and Killing of
Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
[TBL] [Abstract][Full Text] [Related]
11. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
[TBL] [Abstract][Full Text] [Related]
12. The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells.
Laszig S; Boedicker C; Weiser T; Knapp S; Fulda S
Cancer Lett; 2020 Aug; 486():46-57. PubMed ID: 32445837
[TBL] [Abstract][Full Text] [Related]
13. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
Shi C; Yang EJ; Liu Y; Mou PK; Ren G; Shim JS
Oncogene; 2021 Feb; 40(5):937-950. PubMed ID: 33293694
[TBL] [Abstract][Full Text] [Related]
14. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.
Ma Y; Wang L; Neitzel LR; Loganathan SN; Tang N; Qin L; Crispi EE; Guo Y; Knapp S; Beauchamp RD; Lee E; Wang J
Clin Cancer Res; 2017 Apr; 23(8):2027-2037. PubMed ID: 27678457
[No Abstract] [Full Text] [Related]
15. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
16. The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo.
Kuribayashi K; Finnberg N; Jeffers JR; Zambetti GP; El-Deiry WS
Cell Cycle; 2011 Jul; 10(14):2380-9. PubMed ID: 21709442
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of anticancer activity of CBP/p300 inhibitors - Features of their classes, intracellular targets and future perspectives of their application in cancer treatment.
Strachowska M; Robaszkiewicz A
Pharmacol Ther; 2024 May; 257():108636. PubMed ID: 38521246
[TBL] [Abstract][Full Text] [Related]
19. BET inhibition induces synthetic lethality in PTEN deficient colorectal cancers via dual action on p21
Ren G; Chen J; Pu Y; Yang EJ; Tao S; Mou PK; Chen LJ; Zhu W; Chan KL; Luo G; Deng C; Shim JS
Int J Biol Sci; 2024; 20(6):1978-1991. PubMed ID: 38617536
[TBL] [Abstract][Full Text] [Related]
20. Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells.
Yue D; Sun X
Cancer Biol Ther; 2019; 20(3):284-294. PubMed ID: 30359552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
